Hemophilia Treatment Market | Global Industry Analysis 2023

The global hemophilia treatment market size was valued at USD 9,834.7 million in 2022 and is poised to grow at a significant CAGR of 5.2% during the forecast period 2023-29. The primary factors that drive the market are the growing prevalence of bleeding disorders mostly in men across the world, rising healthcare infrastructure, and increasing demand for efficient medication for the treatment.

View the detailed report description here https://www.precisionbusinessinsights.com/market-reports/haemophilia-treatment-market

The global hemophilia treatment market is segmented based on type, products, distribution channel, and region.

Based on the type, the market is segmented into the following:
• Hemophilia A
• Hemophilia B
• Hemophilia C
• Others

Based on the products, the market is segmented into the following:
• Plasma-Derived Coagulation Factor Concentrates
• Recombinant Coagulation Factor Concentrates
• Desmopressin
• Antifibrinolytic Agents

Based on the distribution channel, the market is segmented into the following:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Based on the region, the market is segmented into the following:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Based on type, hemophilia A medication holds the highest market share. The major factor for the rise of this segment is due to increased prevalence of the bleeding disorder, which is caused by the lack or decrease of clotting factor VIII. Hemophilia is caused when blood is unable to clot properly, excessive bleeding occurs after an injury. The rising prevalence of hemophilia observed in the past years, the continuous research and development activities enhance the market growth, in recent studies the current population of males with hemophilia in the United States is estimated to be between 30,000 to 33,000 consequences of high demand for therapeutic agents to prevent from hemophilia. Technological advancement in healthcare for diagnosis drives market growth at a significant rate.

Asia Pacific Haemophilia Treatment Market
Asia Pacific region is expected to grow significantly in the global hemophilia treatment market size over the forecast period. An increasing number of hemophilia patients boost the treatment market with the increased use of prophylactic medication and the rising prevalence of bleeding disorder and their severity. Furthermore, due to rising favorable reimbursement policies in countries like China, India, and Japan, it is expected to boost market growth.

Strategic New Product Launches, Mergers, Acquisitions, and Agreements are the Key Strategies Adopted by Market Players

The global haemophilia treatment market further reveals that the key players are implementing strategies such as the extension of product collection through research and development activities, product launches, acquisitions, mergers, and strategic alliances to improve their market position and strengthen the market revenue share.
In February 2023, The U.S. Food and Drug Administration (FDA) approved ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], previously referred to as efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement therapy.

Request sample report at https://www.precisionbusinessinsights.com/request-sample/?product_id=617421

Key players' profiles in the Haemophilia Treatment Market report are Baxter, Grifols S.A., CSL Limited, Octapharma, Novo Nordisk A/S, Kedrion S.p.A, Pfizer Inc., Bayer AG, Biogen, Shire, F. Hoffmann-La Roche Ltd, Ferring B.V., Sanofi, Swedish Orphan Biovitrum AB (publ), BioMarin, and Sangamo Therapeutics,

Contact:
Mr. Satya
Precision Business Insights | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Website: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet particular research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.